Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gynecologic 1Gastrointestinal 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Leukemia, Myeloid, Acute 15Myelodysplastic Syndromes 10Recurrence 7Ovarian Neoplasms 7Multiple Myeloma 7Pancreatic Neoplasms 6Lymphoma 6Lymphoma, Non-Hodgkin 5Lymphoma, B-Cell 5Colorectal Neoplasms 5Burkitt Lymphoma 5Stomach Neoplasms 4Lymphoma, Large B-Cell, Diffuse 4Leukemia, Myelomonocytic, Chronic 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Hodgkin Disease 4Hematologic Neoplasms 4Sarcoma 3Osteosarcoma 3Lymphoma, Mantle-Cell 3Lymphoma, Follicular 3Leukemia, Biphenotypic, Acute 3Leukemia, B-Cell 3Leukemia 3Colonic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Urogenital Neoplasms 2Triple Negative Breast Neoplasms 2Thymoma 2

Interventions

fludarabine 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thymus Neoplasms × fludarabine × 30 days × Clear all
NCT06885697 2026-06-05

Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

National Institutes of Health Clinical Center (CC)

Phase 1 Recruiting
100 enrolled
GastrointestinalGynecologicOther solid neoplasmThoracic

Colonic Neoplasms, Lung Neoplasms, Mesothelioma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Thymoma, Thymus Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡